ZYME vs. MLYS, WVE, ORIC, NRIX, COGT, SIGA, DNTH, PHAR, SVRA, and CALT
Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Mineralys Therapeutics (MLYS), Wave Life Sciences (WVE), ORIC Pharmaceuticals (ORIC), Nurix Therapeutics (NRIX), Cogent Biosciences (COGT), SIGA Technologies (SIGA), Dianthus Therapeutics (DNTH), Pharming Group (PHAR), Savara (SVRA), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical preparations" industry.
Mineralys Therapeutics (NASDAQ:MLYS) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership.
Mineralys Therapeutics has higher earnings, but lower revenue than Zymeworks. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.
In the previous week, Zymeworks had 6 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 11 mentions for Zymeworks and 5 mentions for Mineralys Therapeutics. Zymeworks' average media sentiment score of 0.20 beat Mineralys Therapeutics' score of -0.19 indicating that Mineralys Therapeutics is being referred to more favorably in the media.
Mineralys Therapeutics has a net margin of 0.00% compared to Mineralys Therapeutics' net margin of -249.63%. Zymeworks' return on equity of -26.48% beat Mineralys Therapeutics' return on equity.
Mineralys Therapeutics currently has a consensus price target of $33.50, indicating a potential upside of 143.64%. Zymeworks has a consensus price target of $14.25, indicating a potential upside of 57.28%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts plainly believe Mineralys Therapeutics is more favorable than Zymeworks.
Zymeworks received 276 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 68.59% of users gave Zymeworks an outperform vote.
84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 33.2% of Mineralys Therapeutics shares are owned by company insiders. Comparatively, 1.2% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Mineralys Therapeutics has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.
Summary
Mineralys Therapeutics beats Zymeworks on 10 of the 17 factors compared between the two stocks.
Get Zymeworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zymeworks Competitors List
Related Companies and Tools
